Final Prospectus filed pursuant to Rule 424(b)(3)
(Registration Number 333-11241)
ENDOGEN, INC.
750,069 Shares of
Common Stock
$.01 Par Value Per Share
---------------
This Prospectus relates to the resale of up to 750,069 shares (the
"Shares") of Common Stock, $.01 par value per share (the "Common Stock"), of
Endogen, Inc. (the "Company") by certain stockholders of the Company (the
"Selling Stockholders"). See "Selling Stockholders." The Shares may be offered
from time to time in transactions on the Nasdaq SmallCap Market, in negotiated
transactions or a combination of such methods of sale, at fixed prices that may
be changed, at market prices prevailing at the time of sale, at prices related
to such prevailing market prices or at negotiated prices. The Selling
Stockholders and certain persons who purchase shares from them, including
broker-dealers acting as principals who may resell the Shares, may be deemed
"underwriters," as that term is defined in the Securities Act of 1933, as
amended (the "Securities Act"). See "Plan of Distribution."
The Company will not receive any of the proceeds from the resale of the
Shares. The Company has agreed to bear all expenses (other than underwriting
discounts and selling commissions, if any, and fees and expenses of counsel or
other advisors to the Selling Stockholders) in connection with the registration
and sale of the Shares being registered hereby. The Company has agreed to
indemnify certain of the Selling Stockholders against certain liabilities,
including liabilities under the Securities Act, as an underwriter or otherwise.
See "Plan of Distribution."
The Company's Common Stock is quoted on the Nasdaq SmallCap Market
under the symbol "ENDG" and on the Boston Stock Exchange under the symbol "EDG."
On November 13, 1996, the closing bid price for the Common Stock as reported by
Nasdaq SmallCap Market was $4.125 per share.
---------------
The Common Stock offered hereby involves a high degree of risk. See "Risk
Factors" beginning on page 6.
---------------
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE
SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS
THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED
UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE
CONTRARY IS A CRIMINAL OFFENSE. ---------------
The date of this Prospectus is November 21, 1996.
<PAGE>
AVAILABLE INFORMATION
The Company is subject to the informational requirements of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), and in
accordance therewith files reports, proxy statements and other information with
the Securities and Exchange Commission (the "Commission"). Such reports, proxy
statements and other information filed by the Company with the Commission
pursuant to the informational requirements of the Exchange Act may be inspected
and copied at the public reference facilities maintained by the Commission at
Judiciary Plaza, Room 1024, 450 Fifth Street, N.W., Washington, D.C. 20549, and
at the following regional offices of the Commission: Seven World Trade Center,
13th Floor, New York, New York 10048 and Citicorp Center, 500 West Madison
Avenue, Suite 1400, Chicago, Illinois 60611-2511. Copies of such material can
also be obtained from the Public Reference Section of the Commission at 450
Fifth Street, N.W., Washington, D.C. 20549 at prescribed rates. The Common Stock
of the Company is traded on the Nasdaq SmallCap Market, and such reports, proxy
statements and other information may also be inspected at the offices of The
Nasdaq Stock Market, Inc., Reports Section, 1735 K Street, N.W., Washington,
D.C. 20006. The Common Stock of the Company is listed on the Boston Stock
Exchange and such material is also available for inspection at the offices of
the Boston Stock Exchange, One Boston Place, Boston, Massachusetts 02109.
The Commission also maintains a Web site that contains reports, proxy
and information statements and other information regarding registrants that file
electronically with the Commission. The address of such site is http:
//www.sec.gov.
The Company has filed with the Commission a Registration Statement on
Form S-3 (including all amendments thereto, the "Registration Statement") under
the Securities Act with respect to the Common Stock offered hereby. This
Prospectus does not contain all of the information set forth in the Registration
Statement, certain parts of which are omitted in accordance with the rules and
regulations of the Commission. For further information regarding the Company and
the Shares offered hereby, reference is hereby made to the Registration
Statement and to the exhibits and schedules filed therewith. Statements
contained in this Prospectus regarding the contents of any agreement or other
document filed as an exhibit to the Registration Statement are not necessarily
complete, and in each instance reference is made to the copy of such agreement
filed as an exhibit to the Registration Statement, each such statement being
qualified in all respects by such reference. The Registration Statement,
including the exhibits and schedules thereto, may be inspected at the public
reference facilities maintained by the Commission at 450 Fifth Street, N.W.,
Washington, D.C. 20549 and copies of all or any part thereof may be obtained
from such office upon payment of the prescribed fees.
DOCUMENTS INCORPORATED BY REFERENCE
The following documents filed by the Company with the Commission (File
No. 0-21354) are incorporated by reference herein, except as superseded or
modified herein:
1. Annual Report on Form 10-K for the fiscal year ended May 31, 1996;
2. Amendment No. 1 to Form 10-K on Form 10-K/A for the fiscal year ended
May 31, 1996;
3. Quarterly Report on Form 10-QSB for the fiscal quarter ended
August 31, 1996;
4. The "Description of Securities" contained in the Company's Registration
Statements on Form 8-A filed on March 11, 1993 and on Form 8-A filed on
April 8, 1994; and
-2-
<PAGE>
5. Current Report on Form 8-K dated March 4, 1996, filed on March 19, 1996,
as amended by Amendment No. 1 to Current Report on Form 8-K/A filed on
May 20, 1996.
All documents filed by the Company pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act after the date of this Prospectus and prior to
the termination of the offering made hereby shall be deemed to be incorporated
by reference in this Prospectus and to be a part hereof from the date of filing
such documents. Any statement contained herein or in a document incorporated or
deemed to be incorporated by reference herein shall be deemed to be modified or
superseded for purposes of this Prospectus to the extent that a statement
contained herein or in any other subsequently filed document which also is or is
deemed to be incorporated by reference herein modifies or supersedes such
statement. Any statement so modified or superseded shall not be deemed, except
as so modified or superseded, to constitute a part of this Prospectus. The
Company will provide without charge to each person to whom this Prospectus is
delivered, upon the written or oral request of any such person, a copy of any
document incorporated herein by reference (other than exhibits unless such
exhibits are specifically incorporated by reference in to such documents).
Requests for such copies should be directed to Mr. Daniel Burns, Financial
Controller, at the principal executive offices of the Company: 30 Commerce Way,
Woburn, Massachusetts 01801, telephone (617) 937-0890. Unless the context
otherwise requires, references in this Prospectus to the "Company" or "Endogen"
refers to Endogen, Inc.
-3-
<PAGE>
PROSPECTUS SUMMARY
The following summary information is qualified in its entirety by the
more detailed information appearing elsewhere in this Prospectus or incorporated
herein by reference and the financial statements which are incorporated herein
by reference.
The Company
Endogen, Inc. ("Endogen") was incorporated on June 1, 1983 and
commenced commercial operations in November 1985. In March 1993, Endogen became
a publicly traded company upon the consummation of the merger of Diagnostics
Holding Corp. ("Diagnostics") with and into Endogen, with Endogen being the
surviving corporation. The shareholders of Diagnostics consisted of all of the
former minority shareholders of Leeco Diagnostics, Inc., a company formerly
traded on the NASD OTC Bulletin BoardSM.
Endogen is a supplier of specialty reagents and immuno-assay test kits
to customers involved in biomedical research, the biotechnology industry and
pharmaceutical drug discovery. Endogen uses monoclonal antibody and recombinant
DNA technology to develop and manufacture products in the field of cytokines and
related immune system factors, the chemical messengers which convey signals
within the immune system.
Endogen offers three major product lines. The first is in vitro
immuno-assay test kits, used for the measurement of human cytokines and related
cell surface proteins in biological samples. The second is in vitro immuno-assay
test kits, used for the measurement of mouse and other species cytokines, an
important and growing area of biomedical research. The third is specialty
reagents, including monoclonal antibodies and recombinant proteins, which are
used by the biomedical research community in the course of basic and applied
research projects. Endogen's product lines provide researchers with tools for
investigating the basic cellular mechanisms underlying the human immune system
and its response to infection, AIDS, cancer and other diseases. Endogen's
products are developed through technology in-licensing agreements with leading
medical institutions and pharmaceutical companies, followed by in-house product
development, validation, manufacturing and quality control.
Endogen's products are sold via catalog and direct selling throughout
the United States and are distributed in approximately 40 other countries
worldwide. Approximately 44% of Endogen's fiscal 1996 sales were exported, and
approximately 33% and 32% of sales were exported in Endogen's fiscal 1995 and
1994, respectively. Endogen has sold its products to almost 1,000 organizations
and institutions including pharmaceutical and biotechnology firms, hospitals,
universities and biomedical research labs worldwide.
The Company's executive office is located at 30 Commerce Way, Woburn,
Massachusetts 01801, and its telephone number is (617) 937-0890.
Risk Factors
The Common Stock offered hereby involves a high degree of risk.
See "Risk Factors."
-4-
<PAGE>
The Offering
<TABLE>
<S> <C>
SECURITIES OFFERED: 750,069 shares of the Company's Common Stock, $.01 par value per share.
OFFERING PRICE: All or part of the Shares offered hereby may be sold from time to time in amounts and on
terms to be determined by the Selling Stockholders at the time of sale.
USE OF PROCEEDS: The Company will receive no part of the proceeds from the sale of any of the Shares by the
Selling Stockholders.
SELLING STOCKHOLDERS: The Shares being offered hereby are being offered for the account of the Selling
Stockholders specified under the caption "Selling Stockholders."
STOCK MARKET SYMBOLS: Nasdaq SmallCap Market Boston Stock Exchange
Common Stock ENDG EDG
</TABLE>
-5-
<PAGE>
RISK FACTORS
In addition to the other information in this Prospectus, the following
factors should be considered carefully in evaluating the Company and its
business before acquiring the Shares offered hereby. This Prospectus contains
forward-looking statements which involve risks and uncertainties. The Company's
actual results could differ materially from those anticipated in these
forward-looking statements as a result of certain factors, including those set
forth in the following risk factors and in the Company's filings with the
Commission.
Capital Requirements.
In the future Endogen may need to raise substantial additional funds
through equity or debt financings, research and development financings,
collaborative relationships or otherwise. Endogen may seek to raise funds
whenever conditions are favorable, even if it does not have an immediate need
for additional capital at that time. There can be no assurance that any such
additional funding will be available to Endogen or, if available, that it will
be on reasonable terms. Any such additional funding may result in significant
dilution to existing shareholders. If adequate funds are not available, Endogen
may be required to significantly curtail its operations or obtain funds through
arrangements with collaborative partners that may require Endogen to relinquish
certain material rights to its products.
Risks Related to Growth through Acquisition.
The Company's strategy is to continue its internal growth and to pursue
additional acquisitions of, or relationships with, other companies as strategic
opportunities arise in the biomedical industry and related industries. As a
result, the Company is subject to certain growth-related risks, including the
risk that it will be unable to retain personnel or acquire other resources
necessary to adequately accommodate such growth. There can be no assurance that
any suitable opportunities for future strategic acquisitions or relationships
will arise or, if they do arise, that the transactions contemplated thereby
could be completed. There can be no assurance that the Company will be able to
integrate effectively into the Company the businesses that the Company has
acquired or those that it may acquire in the future. In addition, such
transactions are subject to various risks generally associated with the
acquisition of businesses, including the financial impact of expenses associated
with the integration of businesses and the diversion of management resources.
There can be no assurance that any recent or future acquisition or other
strategic relationship will not have an adverse impact on the Company's business
or results of operations. If suitable opportunities arise in the future, the
Company anticipates that it would finance such transactions, as well as its
internal growth, through working capital or, in certain instances, through
additional debt or equity financing. There can be no assurance, however, that
such debt or equity financing would be available to the Company on acceptable
terms when, and if, suitable strategic opportunities arise.
Uncertainty of Future Profitability.
To sustain future profitability Endogen must, among other things,
continue to market its current research products and successfully introduce new
products to the market. There can be no assurance that Endogen will be able to
continue manufacturing its current products, successfully develop new products
or that such products, if developed, will be in demand by customers. Endogen
expects to incur substantial expenses over the next several years as its product
lines and operations expand. There can be no assurance that Endogen will be able
to sustain profitability.
Dependence on Technology Licensing.
Endogen is highly dependent on technology and product licensing
arrangements as a principal source for the basic components used in the
development and manufacture of its products. Endogen expects to continue to need
licenses to proprietary cell lines, patents or other proprietary rights of third
parties. No assurance can be given that any licenses required under any such
patents or proprietary rights would be made available on terms acceptable to
Endogen, if at all. In addition, certain of Endogen's technology and product
licenses have been obtained under non-exclusive terms. No assurances can be
given that such technologies or products will not be licensed or commercialized
by competitors and marketed to the same customers.
-6-
<PAGE>
Competition and Risk of Technological Obsolescence.
Competitors of Endogen in the United States and abroad are numerous and
include, among others, biotechnology companies, diagnostics manufacturers and
catalog supply companies. Endogen's success depends upon developing and
maintaining a competitive position in the development of products and
technologies in its area of focus. Competition from other research products and
diagnostics companies is intense and expected to increase as new products enter
the market and new technologies become available. Endogen's competitors may also
succeed in developing technologies and products that are more effective than any
which have been or are being developed by Endogen or that render Endogen's
technologies or products obsolete or noncompetitive. Endogen's competitors may
also succeed in obtaining patent protection or other intellectual property
rights that would block Endogen's ability to develop new products. Finally, many
of these competitors have substantially greater research and development
capabilities, manufacturing, regulatory and marketing experience and financial
and managerial resources than Endogen.
Government Regulation.
Endogen's research and development programs, as well as its
manufacturing and marketing operations, are subject to extensive regulation by
numerous governmental authorities in the United States and other countries.
Certain of Endogen's products are subject to governmental approval for continued
commercial sale. The manufacturing and marketing of additional products in the
future for diagnostic use would be subject to the rigorous testing and approval
processes of the FDA and corresponding foreign regulatory authorities.
Dependence on Proprietary Technology.
Endogen's success will depend, in part, on its ability to preserve its
trade secrets and operate without infringing the proprietary rights of third
parties. Endogen could encounter delays in product market introductions while it
attempts to design around such patents or other rights, or be unable to develop,
manufacture or sell such products.
Endogen also seeks to protect its proprietary technology, including
technology which may not be patented or patentable, in part by confidentiality
agreements and, if applicable, inventors' rights agreements with its
collaborators, advisors, employees and consultants. There can be no assurance
that these agreements will not be breached, that Endogen will have adequate
remedies for any breach, or that Endogen's trade secrets will not otherwise be
disclosed to, or discovered by, competitors.
Commercial Sales and Marketing Requirements.
Endogen currently sells its research products directly to end-users in
the United States and through distributors abroad. While Endogen has expanded
its marketing and sales force, there can be no assurance that Endogen will be
able to further expand its sales and distribution capabilities for the research
market without undue delays or expenditures or that it will be successful in
maintaining market acceptance for its products.
Dependence Upon Key Personnel.
Endogen is highly dependent on the members of its management and
scientific staff, the loss of whom could have a material adverse effect on
Endogen. Endogen also depends on scientific advisors, who may have commitments
that limit their availability to Endogen. In addition, Endogen believes that its
future success will depend in large part upon its ability to attract and retain
highly skilled scientific, managerial and marketing personnel. Endogen faces
significant competition for such personnel from other companies, research and
academic institutions, government entities and other organizations. There can be
no assurance that Endogen will be successful in hiring or retaining the
personnel it requires for continued growth. The failure to hire and retain such
personnel could materially and adversely affect Endogen's prospects.
-7-
<PAGE>
International Operations.
The percentage of revenues from international sales were 44%, 33% and
32% in fiscal years 1996, 1995 and 1994, respectively. Endogen believes that
international sales will continue to represent a significant portion of its
business. Endogen's international business and financial performance may be
adversely affected by such matters as fluctuations in exchange rates, tariff
regulations and difficulties in obtaining export licenses. In addition,
Endogen's business may be adversely affected by lower sales levels that
typically occur during the summer months in Europe and other parts of the world.
USE OF PROCEEDS
The Company will receive no part of the proceeds from the sale of any
of the Shares by any of the Selling Stockholders.
SELLING STOCKHOLDERS
The following table sets forth certain information as of November 1,
1996 with respect to the Shares held by each Selling Stockholder. The Shares may
be offered from time to time by any of the Selling Stockholders. See "Plan of
Distribution."
<TABLE>
<CAPTION>
- ----------------------------------------------------------------------------------------------------------------------------
Number of Number of Number of Shares
Shares Beneficially Owned Prior to Shares Beneficially Owned After
Offering Offered Offering(2)
----------------------------------- --------- ------------------------
Name(1) Number Percentage (3) Number Percentage(3)
- ---- ------ ---------- ------ ----------
<S> <C> <C> <C> <C> <C>
T Cell Diagnostics, Inc.(4) 389,347 11.62% 389,347 0 *
c/o T Cell Science, Inc.
115 Fourth Avenue
Needham, MA 02194
Wolfgang Woloszczuk(5) 46,000 1.54% 28,000 18,000 *
c/o Biomedica GmbH
Divischgasse 4
A-1210 Vienna, Austria
Mag. Martin Wolf 10,000 * 10,000 0 *
Brucknerstrabe 6
A-1040 Vienna, Austria
Biomedica GmbH 127,000 4.29% 127,000 0 *
Divischgasse 4
A-1210 Vienna, Austria
-8-
<PAGE>
Massachusetts Technology 55,500 1.87% 9,000 46,500 1.57%
Development Corporation
148 State Street
Boston, MA 02109
Sensible Solutions, Inc. 6,722 * 6,722 0 *
42 Glen Avenue
Newton Centre, MA 02159
Barber & Bronson Incorporated(6) 180,000 5.73% 180,000 0 *
2101 W. Commercial Blvd.,
Ste. 1500
Ft. Lauderdale, FL 33309
</TABLE>
- -----------------------------------------------------------------------------
* Less than 1%
(1) The persons named in the table have sole voting and investment power with
respect to all shares shown as beneficially owned by them except as noted
in the footnotes below based upon information provided to the Company by
the Selling Stockholders.
(2) Assumes that the Selling Stockholders will sell all of the Shares
registered hereunder. The Selling Stockholders may sell all or any part of
its Shares pursuant to this Prospectus.
(3) The number of shares of Common Stock deemed outstanding includes (i)
2,962,402 shares of Common Stock outstanding as of November 1, 1996 and
(ii) all Common Stock underlying options, warrants and other convertible
securities which are currently exercisable or convertible within 60 days of
November 1, 1996 by the person or entity in question.
(4) Constitutes shares issuable to T Cell Diagnostics, Inc. ("TCD") upon
conversion of the entire principal balance of the Company's Convertible
Subordinated Note due March 1, 2001 (the "Note") issued to TCD.
(5) Dr. Woloszczuk's beneficial ownership includes 18,000 shares issuable upon
the exercise of outstanding stock options exercisable on November 1, 1996
or within 60 days thereafter. Dr. Woloszczuk is an executive officer of
Biomedica GmbH. Excludes 127,000 shares of Common stock beneficially owned
by Biomedica GmbH. Dr. Woloszczuk disclaims beneficial ownership of all
shares held by Biomedica GmbH.
(6) Barber & Bronson Incorporated's beneficial ownership includes 180,000
shares issuable upon the exercise of outstanding warrants exercisable on
November 1, 1996 or within 60 days thereafter. Assumes that Barber &
Bronson Incorporated will receive all of the Shares upon exercise of the
warrants.
Except as noted below, to the best of the Company's knowledge, none of
the Selling Stockholders had any material relationship with the Company or any
of its affiliates within the three year period ending on the date of this
Prospectus.
On March 4, 1996, the Company entered into a purchase agreement (the
"Purchase Agreement") with TCD and T Cell Sciences, Inc. ("TCS") pursuant to
which the Company purchased on such date (i) substantially all of the operating
assets of TCD, a wholly-owned subsidiary of TCS, in exchange for the Note
payable to the order of TCD and additional payments, if any, not determinable at
the time of such acquisition, and (ii) certain facility improvements and
equipment of TCS used in the operation of TCD. The assets acquired by the
Company included all operating assets of TCD relating to its research product
lines and diagnostic products other than its TRAx diagnostic product line. The
purchase price and terms of the acquisition were determined in arms-length
negotiations between the parties. Pursuant to the terms of the Purchase
Agreement, the principal amount due under the Note was increased from $1,900,000
to $2,002,978 to reflect certain post-closing adjustments to the purchase price.
As of November 1, 1996, the Note is convertible into 389,347 shares of the
Company's Common Stock, $.01 par value per share. In the event and to the extent
that TCD elects to convert the Note, the Company will have no obligation to
repay the Note. Pursuant to a registration rights agreement between the Company
and TCD (the "TCD Agreement"), the Company is registering for resale 389,347
shares of Common Stock issuable to TCD upon conversion of the Note, as amended,
and may be resold pursuant to the Registration Statement of which this
Prospectus is a part. This transaction is more fully described in the Company's
Current Report on Form 8-K dated March 4, 1996, as amended, which is
incorporated herein by reference.
-9-
<PAGE>
Wolfgang Woloszczuk has been a director of the Company since November
1990. Dr. Woloszczuk has also served as an executive officer of Biomedica GmbH
("Biomedica") since 1982, of Bionova Handels GmbH since 1988, and of Biocis
Handels GmbH since 1994. Dr. Woloszczuk was an executive officer of Biozol
Diagnostica Vertriebs GmbH ("Biozol") from 1989 until May 1996. In addition, Dr.
Woloszczuk has been a Professor of medicinal chemistry at the University of
Vienna since 1989.
Biomedica is the exclusive distributor for Endogen in Austria and some
former Comecon Countries (i.e., Czech Republic, Hungary, Poland, Slovakia,
Slovenia, Croatia, Bulgaria, Romania). Biomedica is a 50% owner of Biozol. In
1991, the Company entered into a distribution and supply agreement with Biozol
under which Biozol has exclusively distributed the Company's products to
individual country distributors in certain European countries. Effective
September 1, 1996, the agreement has been amended so that the Company will
distribute its products directly to individual country distributors in Europe.
Biozol will continue as the Company's exclusive distributor in Germany. Wolfgang
Woloszczuk, a director of the Company, was an executive officer of Biozol from
1989 until May 1996, and is currently an executive officer of Biomedica GmbH.
Mr. Robert Fein is a director, Vice President, Business Development,
and the beneficial owner of approximately 20% of the outstanding capital stock
of Sensible Solutions, Inc. Mr. Fein provided certain consulting services to the
Company pursuant to a consulting agreement entered into by Mr. Fein and the
Company dated December 15, 1995. As partial consideration for such services, the
Company issued 6,722 shares of Common Stock to Mr. Fein. Mr. Fein transferred
all 6,722 shares to Sensible Solutions, Inc.
Barber & Bronson Incorporated ("B&B") provided certain financial
consulting services to the Company pursuant to a financial consulting services
agreement dated December 15, 1994 (the "B&B Agreement"). As partial
consideration for such services, the Company issued warrants to purchase 180,000
shares of Common Stock to B&B. The Company is registering for resale 180,000
shares underlying the warrants pursuant to certain registration rights set forth
in the B&B Agreement.
The Company is registering the Shares offered hereby for resale by Dr.
Woloszczuk, Mr. Wolf, Biomedica and Massachusetts Technology Development
Corporation ("MTDC") pursuant to the Registration Rights Agreement dated as of
November 30, 1990, as amended on April 4, 1991, by and among the Company, G&G
Diagnostics Limited Partnership ("G&G"), Biozol and MTDC, as amended on March
19, 1993 (the "1991 Registration Rights Agreement").
PLAN OF DISTRIBUTION
The Company will not receive any of the proceeds from this offering,
although the Company will receive a range of $2.00 to $4.00 per share upon the
exercise of the warrants issued to B&B. In the event and to the extent that TCD
elects to convert the Note, the Company will have no obligation to repay the
Note. The Shares offered hereby may be sold from time to time by or for the
account of any of the Selling Stockholders or by their pledgees, donees,
distributees or transferees or other successors in interest to the Selling
Stockholders. The Shares may be sold hereunder directly to purchasers by the
Selling Stockholders in negotiated transactions; by or through brokers or
dealers in ordinary brokerage transactions or transactions in which the broker
solicits purchasers; block trades in which the broker or dealer will attempt to
sell the Shares as agent but may position and resell a portion of the block as
principal; transactions in which a broker or dealer purchases as principal for
resale for its own account; or through underwriters or agents. The Shares may be
sold at a fixed offering price, which may be changed, at the prevailing market
price at the time of sale, at prices related to such prevailing market price or
at negotiated prices. Any brokers, dealers, underwriters or agents may arrange
for others to participate in any such transaction and may receive compensation
in the form of discounts, commissions or concessions from the Selling
Stockholders and/or the purchasers of the Shares. Each Selling Stockholder will
be responsible for payment of any and all commissions to brokers. The Company
has agreed to indemnify certain of the Selling Stockholders against certain
liabilities, including liabilities under the Securities Act, as an underwriter
or otherwise.
Pursuant to the 1991 Registration Rights Agreement, the TCD Agreement,
and the B&B Agreement, the Company has agreed, at its expense, to file the
registration statement to which this Prospectus is a part and to take certain
-10-
<PAGE>
other actions to permit the Selling Stockholders to sell the Shares under the
Securities Act and applicable state securities laws. The aggregate proceeds to
any Selling Stockholder from the sale of the Shares offered by the Selling
Stockholder hereby will be the purchase price of such Shares less any broker's
commissions.
In order to comply with the securities laws of certain states, if
applicable, the Shares will be sold in such jurisdiction only through registered
or licensed brokers or dealers. In addition, in certain states the Shares may
not be sold unless they have been registered or qualified for sale in the
applicable state or an exemption from the registration or qualification
requirement is available and is complied with.
Any Selling Stockholder and any broker-dealer, agent or underwriter
that participates with the Selling Stockholder in the distribution of the Shares
may be deemed to be "underwriters" within the meaning of the Securities Act, in
which event any commissions received by such broker-dealers, agents or
underwriters and any profit on the resale of the Shares purchased by them may be
deemed to be underwriting commissions or discounts under the Securities Act.
The Selling Stockholders are not restricted as to the price or prices
at which they may sell Shares. Sales of such Shares at less than the market
prices may depress the market price of the Company's securities. Moreover, the
Selling Stockholders are not restricted as to the number of Shares which may be
sold at any one time, and it is possible that a significant number of Shares
could be sold at the same time which may also have a depressive effect on the
market price of the Company's securities. It is anticipated that the sale of the
Shares will be made over the three-year period commencing with the date of this
Prospectus.
Under applicable rules and regulations under the Exchange Act, any
person engaged in the distribution of the Shares offered hereby may not
simultaneously engage in market making activities with respect to the Shares for
a period of two business days prior to the commencement of such distribution. In
addition, and without limiting the foregoing, each Selling Stockholder will be
subject to applicable provisions of the Exchange Act and the rules and
regulations thereunder, including, without limitation, Rules 10b-2, 10b-5, 10b-6
and 10b-7, which provisions may limit the timing of purchases and sales of the
Shares by the Selling Stockholder.
There is no assurance that any Selling Stockholder will sell any or all
of the Shares described herein and may transfer, devise or gift such securities
by other means not described herein.
The Company will use its best efforts to cause the Registration
Statement to which this Prospectus relates to become effective as promptly as is
practicable and to keep the Registration Statement effective until the earlier
to occur of (i) thirty-six months after the date on which the Commission
declares the Registration Statement effective and (ii) such earlier time as all
Shares have been disposed of in a manner permitting resale without further
registration thereof under the Securities Act. Expenses of preparing and filing
the Registration Statement and all post-effective amendments will be borne by
the Company.
LEGAL MATTERS
Certain legal matters with respect to the Shares offered hereby will be
passed upon for the Company by Testa, Hurwitz & Thibeault, LLP, Boston,
Massachusetts.
EXPERTS
The financial statements incorporated in this Prospectus by reference
to the Annual Report on Form 10-K/A, of Endogen, Inc. for the year ended May 31,
1996 have been so incorporated in reliance on the report of Price Waterhouse
LLP, independent accountants, given on the authority of said firm as experts in
auditing and accounting.
The financial statements of the research products and operations of T
Cell Diagnostics, Inc. for each of the three years in the period ended December
31, 1995, incorporated by reference in this Prospectus, have been incorporated
herein in reliance on the report of Price Waterhouse LLP, independent
accountants, given on the authority of such firm as experts in accounting and
auditing.
-11-
<PAGE>
DISCLOSURE OF COMMISSION POSITION
ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES
Certain of the Selling Stockholders have agreed to indemnify the
Company's directors, officers and controlling persons against certain
liabilities under the Securities Act pursuant to the 1991 Registration Rights
Agreement, the TCD Agreement and the B&B Agreement.
Section 67 of the Massachusetts Business Corporation Law ("Section
67") provides that a corporation may indemnify its directors and officers to the
extent specified in or authorized by (i) the articles of organization; (ii) a
by-law adopted by the stockholders, or (iii) a vote adopted by the holders of a
majority of the shares of stock entitled to vote on the election of directors.
In all instances, the extent to which a corporation provides indemnification to
its directors and officers under Section 67 is optional. The Company's By-laws
provide that each director and officer shall be indemnified by the Company
against liabilities and expenses in connection with any legal proceeding to
which such officer or director may become a party by reason of being or having
been an officer or director unless otherwise prohibited by law.
Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and controlling persons
of the Company pursuant to the foregoing provisions, or otherwise, the Company
has been advised that in the opinion of the Commission such indemnification is
against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment by the Company of expenses incurred or paid
by a director, officer or controlling person of the Company in the successful
defense of any action, suit or proceeding) is asserted by such director, officer
or controlling person in connection with the securities being registered, the
Company will, unless in the opinion of its counsel the matter has been settled
by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as
expressed in the Securities Act and will be governed by the final adjudication
of such issue.
-12-
<PAGE>
================================================================================
No person has been authorized to give any information or to
make any representation other than those contained in this
Prospectus in connection with the offering made hereby, and
if given or made, such information or representation must
not be relied upon as having been authorized by the Company
or by any other person. Neither the delivery of this
Prospectus nor any sale made hereunder shall, under any
circumstances, create any implication that information
herein is correct as of that information herein is correct
as of any time subsequent to the date hereof. This
Prospectus does not constitute an offer to sell or a
solicitation of any person in any jurisdiction in which such
offer or solicitation may not be lawfully made.
---------------------
TABLE OF CONTENTS
Page
Available Information .............................. 2
Documents Incorporated by Reference ................. 2
Prospectus Summary ................................. 4
Risk Factors ....................................... 6
Use of Proceeds .................................... 8
Selling Stockholders ............................... 8
Plan of Distribution ............................... 10
Legal Matters ...................................... 11
Experts ............................................ 11
Disclosure of Commission Position on
Indemnification for Securities Act Liabilities ..... 12
750,069 Shares
ENDOGEN, INC.
Common Stock
-----------------
PROSPECTUS
-----------------
November 21, 1996
================================================================================
